Mr. Payton Nyquvest reports

NUMINUS WELLNESS SUBMITS CLINICAL TRIAL APPLICATION

Numinus Wellness Inc. has submitted a clinical trial application to Health Canada to examine the feasibility of a group model in MDMA-assisted (3,4-methylenedioxymethamphetamine) psychotherapy, enrolling trainee practitioners as participants.

If approved, the trial would allow Numinus to study MDMA-assisted psychotherapy with groups and better understand the optimum number of therapists required to deliver the programs safely. It may also provide eligible trainees with the opportunity to build core competencies and legally experience MDMA.

"As research into MDMA's efficacy in addressing serious mental conditions is increasing, it is particularly important that practitioners advance their knowledge of optimum delivery in a clinical setting," said Payton Nyquvest, founder and chief executive officer of Numinus. "Our goal in designing this study is to explore the feasibility of a group model and take steps to help establish best practices in group-based therapy for MDMA and contribute to the body of evidence of its safety."

"Considering the large potential patient population that could be seeking care should MDMA-assisted therapy receive approval, it will be essential for clinics and practitioners to gain the knowledge and experience to deliver this groundbreaking treatment for PTSD [posttraumatic stress disorder]," added Dr. Rick Doblin, PhD, an unpaid volunteer Numinus strategic adviser. "This study has the potential to significantly enhance patient outcomes by providing a means for practitioners to gain valuable insights."

The clinical trial is formally titled "Phase 1 Exploration of Feasibility and Optimal Therapist Numbers in Group Model MDMA-Assisted Psychotherapy: A Study on Safety, Delivery, and Practitioner Training." If approved, it will be the first of its kind. Details on participating in the clinical trial will be posted on the Numinus website.

About Numinus Wellness Inc.

Numinus Wellness helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model -- including psychedelic research, clinic care and practitioner training -- is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, the company is leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.

We seek Safe Harbor.